All News

RheumNow Podcast square

RheumNow Podcast – Great Associations (3.19.2021)

Jack Cush, MD

Dr. Jack Cush rants on the journal reports, news and FDA actions featured this past week on RheumNow.com.

Read Article
Super RA superman

Are You a Super Rheum?

Jack Cush, MD

Several weeks ago, at the Rheumatology Winter Clinical Symposia, an interesting debate between Drs. Orrin Troum and Marty Bergman hashed over the concept of whether rheumatologists should sub-specialize with a practice, research or career devoted to one disease ("Super Rheum"), or be "selective" about what disorders and diseases they would treat or just be a generalist. 

Read Article
heels%20hurtin.jpg

Enthesitis Responses to Secukinumab in Spondylitis Patients

Jack Cush, MD

Schett and colleagues studies the secukinumab (an IL-17 inhibitor) response in patients from 3 clinical trials with enthesitis and ankylosing spondylitis (AS) and demonstrated consistent efficacy with improved enthesitis scores at both peripheral and axial sites.

Read Article
colitis.jpg

Low IBD Risk with IL-17 Inhibition

Jack Cush, MD

Incident or worsening colitis is a rare complication of IL-17 inhibitor therapy; a real world study confirms very low rates of new IBD in patients starting secukinumab.

Read Article
Lumbar rash DM

MAXIMISE Trial - Secukinumab Efficacy in Psoriatic Spondylitis Patients

Jack Cush, MD

The results of the novel MAXIMISE trial have been published, demonstrating that secukinumab significantly improved axial signs and symptoms in psoriatic arthritis patients with axial manifestations with inadequate NSAID response.

Read Article
RheumNow Podcast square

RheumNow Podcast – Sweet Lies or Hard Truths? (2.26.2021)

Jack Cush, MD

Dr. Jack Cush reviews and discusses the news and Journal reports from the past week on RheumNow.com.

Read Article
Top 4 arthritis types that significantly increase the risk of CVA: 1) RA (RR=1.38), 2) ankylosing spondylitis (RR=1.49), 3) psoriatic arthritis (RR=1.33) & gout (RR=1.4). With these, the risk was higher in younger (<45 yrs) (RR = 1.46), not older (>65) https://t.co/Snb6OrtZJH

Links:

Dr. John Cush RheumNow ( View Tweet)

Phase III RCT of apremilast showed no benefit in ankylosing spondylitis pts. 490 AS pts recv placebo or apremilast 20 mg or 30 mg bid 24 wks. The ASAS 20 was the same in all groups (PBO: 37%; 20 mg 35%; 30 mg 33). 2 yrs Xray changes were equal too. https://t.co/ILYtVMZp80

Links:

Dr. John Cush RheumNow ( View Tweet)

News Feature: Enthesitis Responses to Secukinumab in Spondylitis Patients https://t.co/U7qfwwA2as https://t.co/lFa5LdfkIZ

Links:

Dr. John Cush RheumNow ( View Tweet)
The Reflecting Rheum: 2020 SpA and Still’s Disease Highlights Sponsored by Novartis Medical Affairs Listen to a discussion of medical experts share their views on the most impactful work done in spondyloarthritis and Still’s disease in 2020. https://t.co/rxTAwQNalx https://t.co/HixhdoIIcB

Links:

Dr. John Cush RheumNow ( View Tweet)
We are three weeks out from RheumNow Live. Are you planning on attending? https://t.co/vJlU0Z3Q3x

Links:

Dr. John Cush RheumNow ( View Tweet)

Data from Danish Medical Birth Register shows PREG women w/ spondyloarthritis have more adverse pregnancy outcomes - including preterm birth (OR 1.5), elective C-section (OR 1.44), & epidurals (OR 1.11). Not increased were preeclampsia & rate small wt. https://t.co/opYsOBAR6A

Links:

Dr. John Cush RheumNow ( View Tweet)

Survery of 438 RHEUMS on #AS & SpA - half use mod NY & ASAS criteria. 3/4 say Inflammatory Back Pain is axSpA specific, ~1/2 say uveitis/dactylitis are “very specific; less so heel enthesitis, peripheral arthritis. SI MRI was mor common w/ younger Rheums https://t.co/xfjvK5TO0t

Links:

Dr. John Cush RheumNow ( View Tweet)

RWCS Highlights - Day 2 by Dr. Rachel Tate ( @uptotate) -What’s new in Spondyloarthritis -Osteoporosis and Beyond -Immunologic basis and clinical characteristics https://t.co/q4lI2BYhfz https://t.co/Q79CHaQrHf

Links:

Dr. John Cush RheumNow ( View Tweet)
Upadacitinib works very well in ankylosing spondylitis. Will JAKs soon be approved in #AS @RWCSmtg @JointMD https://t.co/09KFo3mYJs
Dr. John Cush RheumNow ( View Tweet)
Tofacitinib shown to work very well in ankylosing spondylitis. @RWCSmtg @JointMD https://t.co/r1yIL96HyQ
Dr. John Cush RheumNow ( View Tweet)
But.... Etanercept was not effective in a small study of "pre-axSpA"(not having MRI SI or Elevated CRP. Low level responses in this study @RWCSmtg @JointMD https://t.co/ofIbByefMH
Dr. John Cush RheumNow ( View Tweet)
Eranercept works in nonrad AxSpA @RWCSmtg @JointMD https://t.co/PFTqNj6R3s
Dr. John Cush RheumNow ( View Tweet)
TICOSPA,. Right control in axSpA didn't work so well, even though the TV group water twice as likely to get advanced therapies @RWCSmtg @JointMD https://t.co/Jm9vHAPwCN
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman shows x-ray progression is different/lower in non radiographic AxSpA @RWCSmtg https://t.co/tqI3xKhDuJ
Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×